407 related articles for article (PubMed ID: 25724135)
1. Enteric-coated capsules filled with mono-disperse micro-particles containing PLGA-lipid-PEG nanoparticles for oral delivery of insulin.
Yu F; Li Y; Liu CS; Chen Q; Wang GH; Guo W; Wu XE; Li DH; Wu WD; Chen XD
Int J Pharm; 2015 Apr; 484(1-2):181-91. PubMed ID: 25724135
[TBL] [Abstract][Full Text] [Related]
2. N-trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption.
Sheng J; Han L; Qin J; Ru G; Li R; Wu L; Cui D; Yang P; He Y; Wang J
ACS Appl Mater Interfaces; 2015 Jul; 7(28):15430-41. PubMed ID: 26111015
[TBL] [Abstract][Full Text] [Related]
3. [Study on preparation and oral efficacy of insulin-loaded poly(lactic-co-glycolic acid) nanoparticles].
Pan Y; Xu H; Zhao HY; Wei G; Zheng JM
Yao Xue Xue Bao; 2002 May; 37(5):374-7. PubMed ID: 12579845
[TBL] [Abstract][Full Text] [Related]
4. In vitro uptake evaluation in Caco-2 cells and in vivo results in diabetic rats of insulin-loaded PLGA nanoparticles.
Reix N; Parat A; Seyfritz E; Van der Werf R; Epure V; Ebel N; Danicher L; Marchioni E; Jeandidier N; Pinget M; Frère Y; Sigrist S
Int J Pharm; 2012 Nov; 437(1-2):213-20. PubMed ID: 22940208
[TBL] [Abstract][Full Text] [Related]
5. HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin.
Wu ZM; Zhou L; Guo XD; Jiang W; Ling L; Qian Y; Luo KQ; Zhang LJ
Int J Pharm; 2012 Apr; 425(1-2):1-8. PubMed ID: 22248666
[TBL] [Abstract][Full Text] [Related]
6. Novel PLGA-based nanoparticles for the oral delivery of insulin.
Malathi S; Nandhakumar P; Pandiyan V; Webster TJ; Balasubramanian S
Int J Nanomedicine; 2015; 10():2207-18. PubMed ID: 25848248
[TBL] [Abstract][Full Text] [Related]
7. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.
Patel B; Gupta V; Ahsan F
J Control Release; 2012 Sep; 162(2):310-20. PubMed ID: 22800582
[TBL] [Abstract][Full Text] [Related]
8. Development of a non-toxic and non-denaturing formulation process for encapsulation of SDF-1α into PLGA/PEG-PLGA nanoparticles to achieve sustained release.
Haji Mansor M; Najberg M; Contini A; Alvarez-Lorenzo C; Garcion E; Jérôme C; Boury F
Eur J Pharm Biopharm; 2018 Apr; 125():38-50. PubMed ID: 29325770
[TBL] [Abstract][Full Text] [Related]
9. PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium.
Gholizadeh S; Kamps JAAM; Hennink WE; Kok RJ
Int J Pharm; 2018 Sep; 548(2):747-758. PubMed ID: 29042337
[TBL] [Abstract][Full Text] [Related]
10. Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin.
Jain S; Rathi VV; Jain AK; Das M; Godugu C
Nanomedicine (Lond); 2012 Sep; 7(9):1311-37. PubMed ID: 22583576
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, and evaluation in vivo of Ins-SiO₂-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin.
Zhao X; Shan C; Zu Y; Zhang Y; Wang W; Wang K; Sui X; Li R
Int J Pharm; 2013 Sep; 454(1):278-84. PubMed ID: 23830939
[TBL] [Abstract][Full Text] [Related]
12. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats.
Li Y; Pei Y; Zhang X; Gu Z; Zhou Z; Yuan W; Zhou J; Zhu J; Gao X
J Control Release; 2001 Apr; 71(2):203-11. PubMed ID: 11274752
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats.
Khalil NM; do Nascimento TC; Casa DM; Dalmolin LF; de Mattos AC; Hoss I; Romano MA; Mainardes RM
Colloids Surf B Biointerfaces; 2013 Jan; 101():353-60. PubMed ID: 23010041
[TBL] [Abstract][Full Text] [Related]
14. Self-nanoemulsifying drug delivery systems for oral insulin delivery: in vitro and in vivo evaluations of enteric coating and drug loading.
Li P; Tan A; Prestidge CA; Nielsen HM; Müllertz A
Int J Pharm; 2014 Dec; 477(1-2):390-8. PubMed ID: 25455781
[TBL] [Abstract][Full Text] [Related]
15. [Poly(arginine)8 enhanced intestinal absorption of insulin-loaded nanoparticles].
Liu XL; Zhang WJ; Wei G; Lu WY
Yao Xue Xue Bao; 2012 Apr; 47(4):512-6. PubMed ID: 22799036
[TBL] [Abstract][Full Text] [Related]
16. Folate-decorated PEG-PLGA nanoparticles with silica shells for capecitabine controlled and targeted delivery.
Wei K; Peng X; Zou F
Int J Pharm; 2014 Apr; 464(1-2):225-33. PubMed ID: 24463073
[TBL] [Abstract][Full Text] [Related]
17. Isoniazid loaded core shell nanoparticles derived from PLGA-PEG-PLGA tri-block copolymers: in vitro and in vivo drug release.
Gajendiran M; Gopi V; Elangovan V; Murali RV; Balasubramanian S
Colloids Surf B Biointerfaces; 2013 Apr; 104():107-15. PubMed ID: 23298594
[TBL] [Abstract][Full Text] [Related]
18. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery.
Su FY; Lin KJ; Sonaje K; Wey SP; Yen TC; Ho YC; Panda N; Chuang EY; Maiti B; Sung HW
Biomaterials; 2012 Mar; 33(9):2801-11. PubMed ID: 22243802
[TBL] [Abstract][Full Text] [Related]
19. A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles.
Peng Q; Zhang ZR; Gong T; Chen GQ; Sun X
Biomaterials; 2012 Feb; 33(5):1583-8. PubMed ID: 22112760
[TBL] [Abstract][Full Text] [Related]
20. Lyophilized insulin nanoparticles prepared from quaternized N-aryl derivatives of chitosan as a new strategy for oral delivery of insulin: in vitro, ex vivo and in vivo characterizations.
Mahjub R; Radmehr M; Dorkoosh FA; Ostad SN; Rafiee-Tehrani M
Drug Dev Ind Pharm; 2014 Dec; 40(12):1645-59. PubMed ID: 24093431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
